Univalent antibodies kill tumour cells in vitro and in vivo

Ex vivo assays of dendritic cell activation and cytokine profiles as predictors of in vivo effects in an anti-human CD40 monoclonal antibody ChiLob 7/4 phase I trial.

Cancer immunology research·2014

The application of monoclonal antibodies in the treatment of lymphoma.

Methods in molecular medicine·2011

Guidelines for the welfare and use of animals in cancer research.

British journal of cancer·2010

Epidermal growth factor receptor and g250: useful target antigens for antibody mediated cellular cytotoxicity against renal cell carcinoma?

The Journal of urology·2002

Engineered antibody for treating lymphoma.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2002

Analysis of the oligomeric requirement for signaling by CD40 using soluble multimeric forms of its ligand, CD154.

European journal of immunology·2001

A thermodynamically favoured molecular computer.

Nature·2026

Molecular-level observation of the self-assembly of a virus-like particle.

Nature·2026

Heterogeneous photonic integration of single-crystalline nanomembranes.

Nature·2026

Assessing biological degradation of non-hydrolysable synthetic polymers.

Nature·2026

Electrically controllable superconducting memory effect in UTe2.

Nature·2026

Continuous-wave laser absorption spectroscopy of the thorium-229 nucleus.

Nature·2026

[Regulatory T Cells and Cancer-Focus on Renal Cell Carcinoma].

Gan to kagaku ryoho. Cancer & chemotherapy·2026

Identification of broadly tumour-reactive γδ TCRs from multiple myeloma.

Nature·2026

Immunogenic cell death and tertiary lymphoid structures: bridging tumour cell death and immune organization.

Nature reviews. Immunology·2026

Sentinel lymph node biopsy in melanoma: Redundant in the neoadjuvant era.

European journal of cancer (Oxford, England : 1990)·2026

Accountability and the seemingly imponderables in NHS patient safety.

British journal of nursing (Mark Allen Publishing)·2026

MG53 suppresses IRF7 to reprogram macrophages and promote antitumor immunity in pancreatic ductal adenocarcinoma.

Cell reports·2026

Related Experiment Videos

Univalent antibodies kill tumour cells in vitro and in vivo

Related Concept Videos

Ex vivo assays of dendritic cell activation and cytokine profiles as predictors of in vivo effects in an anti-human CD40 monoclonal antibody ChiLob 7/4 phase I trial.

The application of monoclonal antibodies in the treatment of lymphoma.

Guidelines for the welfare and use of animals in cancer research.

Epidermal growth factor receptor and g250: useful target antigens for antibody mediated cellular cytotoxicity against renal cell carcinoma?

Engineered antibody for treating lymphoma.

Analysis of the oligomeric requirement for signaling by CD40 using soluble multimeric forms of its ligand, CD154.

A thermodynamically favoured molecular computer.

Molecular-level observation of the self-assembly of a virus-like particle.

Heterogeneous photonic integration of single-crystalline nanomembranes.

Assessing biological degradation of non-hydrolysable synthetic polymers.

Electrically controllable superconducting memory effect in UTe2.

Continuous-wave laser absorption spectroscopy of the thorium-229 nucleus.

[Regulatory T Cells and Cancer-Focus on Renal Cell Carcinoma].

Identification of broadly tumour-reactive γδ TCRs from multiple myeloma.

Immunogenic cell death and tertiary lymphoid structures: bridging tumour cell death and immune organization.

Sentinel lymph node biopsy in melanoma: Redundant in the neoadjuvant era.

Accountability and the seemingly imponderables in NHS patient safety.

MG53 suppresses IRF7 to reprogram macrophages and promote antitumor immunity in pancreatic ductal adenocarcinoma.

Related Experiment Videos

Univalent antibodies kill tumour cells in vitro and in vivo

Related Concept Videos

Related Articles